Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Rapoport, Bernardo Leon![]() |
|
dc.contributor.author | Nayler, Simon![]() |
|
dc.contributor.author | Mlecnik, Bernhard![]() |
|
dc.contributor.author | Smit, Teresa![]() |
|
dc.contributor.author | Heyman, Heino Martin![]() |
|
dc.contributor.author | Bouquet, Isabelle![]() |
|
dc.contributor.author | Martel, Marine![]() |
|
dc.contributor.author | Galon, Jerome![]() |
|
dc.contributor.author | Benn, Carol-Ann![]() |
|
dc.contributor.author | Anderson, Ronald![]() |
|
dc.date.accessioned | 2022-07-14T07:14:47Z | |
dc.date.available | 2022-07-14T07:14:47Z | |
dc.date.issued | 2022-05-20 | |
dc.description.abstract | BACKGROUND : Tumor-infiltrating lymphocytes are associated with a better prognosis in early triple-negative breast cancer (TNBC). These cells can be enumerated in situ by the “Immunoscore Clinical Research” (ISCR). The original Immunoscore® is a prognostic tool that categorizes the densities of CD3+ and CD8+ cells in both the invasive margin (IM) and center of the tumor (CT) in localized colon cancer, yielding a five-tiered classification (0–4). We evaluated the prognostic potential of ISCR and pathological complete response (pCR) following neoadjuvant chemotherapy (NACT). METHODS : The cohort included 53 TNBC, 32 luminal BC, and 18 HER2-positive BC patients undergoing NACT. Pre-treatment tumor biopsies were immune-stained for CD3+ and CD8+ T-cell markers. Quantitative analysis of these cells in different tumor locations was performed using computer-assisted image analysis. RESULTS : The pCR rate was 44%. Univariate analysis showed that primary tumor size, estrogen-receptor negative, progesteronereceptor negative, luminal vs. HER2-positive vs. TNBC, high Ki-67, high densities (cells/mm2 ) of CD3 CT, CD8+ CT, CD3+ IM, and CD8+ IM cells were associated with a high pCR. ISCR was associated with pCR following NACT. A multivariate model consisting of ISCR and the significant variables from the univariate analysis showed a significant trend for ISCR; however, the low sample size did not provide enough power for the model to be included in this study. CONCLUSIONS : These results revealed a significant prognostic role for the spatial distributions of the CD3+ , and CD8+ lymphocytes, as well as the ISCR in relation to pCR following NACT. | en_US |
dc.description.department | Immunology | en_US |
dc.description.librarian | dm2022 | en_US |
dc.description.sponsorship | Medical Oncology Centre of Rosebank | en_US |
dc.description.uri | https://www.mdpi.com/journal/cancers | en_US |
dc.identifier.citation | Rapoport, B.L.; Nayler, S.; Mlecnik, B.; Smit, T.; Heyman, L.; Bouquet, I.; Martel, M.; Galon, J.; Benn, C.-A.; Anderson, R. Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+ , CD8+ , and Immunoscore Are Associated with a Pathological Complete Response. Cancers 2022, 14, 2525. https://doi.org/10.3390/cancers14102525. | en_US |
dc.identifier.issn | 2072-6694 (online) | |
dc.identifier.other | 10.3390/cancers14102525 | |
dc.identifier.uri | https://repository.up.ac.za/handle/2263/86164 | |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.rights | © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en_US |
dc.subject | CD3+ lymphocytes | en_US |
dc.subject | CD8+ lymphocytes | en_US |
dc.subject | Early breast cancer | en_US |
dc.subject | HER2-positive breast cancer | en_US |
dc.subject | Ki-67 | en_US |
dc.subject | Luminal breast cancer | en_US |
dc.subject | Tumor-infiltrating lymphocytes (TILs) | en_US |
dc.subject | Triple-negative breast cancer (TNBC) | en_US |
dc.subject | Immunoscore clinical research (ISCR) | en_US |
dc.title | Tumor-Infiltrating lymphocytes (TILs) in early breast cancer patients: high CD3+ , CD8+ , and Immunoscore are associated with a pathological complete response | en_US |
dc.type | Article | en_US |